Taysha Gene Therapies Q2 EPS $(0.38) Misses $(0.31) Estimate, Sales $2.40M Beat $1.86M Estimate
Portfolio Pulse from Benzinga Newsdesk
Taysha Gene Therapies reported Q2 losses of $(0.38) per share, missing the analyst consensus estimate of $(0.31) by 22.58%. However, the company's quarterly sales of $2.40 million beat the analyst consensus estimate of $1.86 million by 28.76%.
August 14, 2023 | 11:11 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Taysha Gene Therapies' Q2 earnings per share missed estimates, but sales exceeded expectations.
Taysha Gene Therapies' Q2 earnings per share missed the analyst consensus estimate, which could negatively impact the stock. However, the company's sales exceeded expectations, which could offset the negative impact of the earnings miss.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100